Please login to the form below

Not currently logged in

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment


Agreement reached between EU27 leaders in the early hours of Thursday means the UK’s exit has now been pushed back to 31 October, giving the country more time to find its way out of the Brexit crisis.

This is the second time the UK’s exit date has been delayed, reflecting an absolute deadlock in a divided Parliament and Government cabinet about Brexit, nearly three years on since the referendum.

Prime Minister Theresa May’s actions have made it clear that she believes a no-deal Brexit should be avoided at all costs, and legions of civil servants have, for the time being at least, been stood down from their no-deal planning roles.

Many commentators believe this means the risk of the UK crashing out without a deal have receded, while the likelihood of a ‘softer’ Brexit (such as a customs union) or a second referendum have increased.

However, there remains no clear route to a solution to the crisis, with very limited belief that the current talks between the Conservative Government and the Labour party will yield a viable solution.

While business leaders were pleased that the threat of a no-deal Brexit has been averted for a second time, they warn that prolonging the uncertainty will mean companies will continue to withhold investment.

Overall capital spending in the UK across all business sectors has declined for four consecutive quarters, the longest sustained fall (the recession excepted) since 2003.

Pharma industry association the ABPI and biotech association the BIA are part of the Brexit Health Alliance, a coalition bringing together the NHS and industry to produce a co-ordinated response to Brexit.

Niall Dickson, Brexit Health Alliance co-chair and NHS Confederation chief executive, responded to yesterday’s new extension by saying a no-deal exit today “would have been bad for patients so it is a relief that threat has gone away, for now.”

He added: “But of course the extension leaves that as one potential outcome, which means everyone involved in healthcare must continue to prepare for this possibility and keep contingency plans in place.

Dickson echoed remarks from many business associations, warning that this new breathing space should not be wasted.

“We are now in a 'phoney war' and the risk is complacency – the system needs to assume we could crash out and do everything we can to make sure patients are protected if that happens."

He concluded: “Like everyone else in the UK and Europe we want an end to this circus of uncertainty and we need to see the political will to bring that about.”

For the pharma industry, the extended delay will add not only uncertainty, but extra cost, as it has to maintain additional stockpiles of medicines and other no-deal supply chain measures.

Mike Thompson

The ABPI's Mike Thompson

Mike Thompson, chief executive of the ABPI said: “Companies are doing everything they can to protect the supply of medicines whatever the Brexit outcome. As part of this they have increased stocks of medicines in line with Government guidance.”

“With the extension of Article 50, we will work with Government to consider how best to prepare and review whether current plans for a no deal Brexit are still appropriate.”

An ABPI spokesperson told PME that the industry will not be complacent about any perceived move away from a no-deal Brexit, and said the organisation was engaged in discussions with the government about next steps.

Article by
Andrew McConaghie

12th April 2019

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...